Leads Biolabs and DNTH initiate trial of LBL-047 in SLE
Leads Biolabs and Dianthus Therapeutics (DNTH) have initiated a Phase I clinical trial investigating LBL-047 in healthy volunteers and patients…
All articles by Salong Debbarma
Salong Debbarma
-
-
AusperBio concludes enrolment in Phase III AUSHINE trial
AusperBio has completed patient enrolment for the Phase III AUSHINE clinical trial evaluating AHB-137 for chronic hepatitis B (CHB). The…
-
Altimmune reports positive topline results from IMPACT Phase IIb trial
Altimmune has announced positive topline results from the IMPACT Phase IIb trial of pemvidutide, a balanced 1:1 glucagon/GLP-1 dual receptor…
-
Soligenix reports Phase IIa SGX945 trial data for Behçet’s disease
Soligenix has reported positive data from its Phase IIa trial of SGX945 (dusquetide) for the treatment of Behçet's disease. The…
-
Qihan Biotech begins subject dosing in Phase I/IIa study of QT-019B for rSLE
Qihan Biotech has commenced patient dosing in a Phase I/IIa clinical trial of the allogeneic chimeric antigen receptor T-cell (CAR-T)…
-
Novartis reports positive data from VAYHIT2 trial for immune thrombocytopenia
Novartis has reported positive outcomes from the VAYHIT2 Phase III trial assessing ianalumab plus eltrombopag to treat patients with primary immune…
-
Daiichi Sankyo announces first patient dosed in Phase III trial of Enhertu
Daiichi Sankyo has announced the dosing of first patient in the DESTINY-Ovarian01 Phase III trial’s randomisation phase, assessing Enhertu (trastuzumab…
-
Structure Therapeutics announces positive results from aleniglipron trial
Structure Therapeutics has reported positive topline results from the ACCESS clinical programme for its investigational oral glucagon-like-peptide-1 (GLP-1) receptor agonist,…
-
Citryll doses first patient in Citylights trial for hidradenitis suppurativa
Citryll has dosed the first patient in the Phase IIa Citylights clinical trial of the monoclonal antibody, CIT-013, for moderate-to-severe…
-
Eli Lilly reports Phase III trial results of Jaypirca for CLL/SLL
Eli Lilly and Company has reported the outcomes from the Phase III BRUIN CLL-314 trial of Jaypirca (pirtobrutinib), a non-covalent…